On November 8, 2018, RNA Diagnostics announced the closing of their $5 million Series A financing round led by iGan Partners. The funding will be used for continued progress in the trial of RNA Diagnostics’ BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) trial, as well as the further development and commercialization of the organization’s RNA Disruption Assay test.
iGan Partners is a Toronto based Venture Capital firm with a focus on Canadian health technology. iGan Partners invests in entrepreneurs to commercialize and scale their disruptive innovations in healthcare, and provides companies with active support and access to a network of industry partners.
RNA Diagnostics is a Canadian company specializing in patented platform technology that provides real-time cancer therapy guidance.
Osler, Hoskin & Harcourt LLP advised iGan with a team consisting of Andre Perey, Michael Grantmyre, and Alana McElhinney (Emerging and High Growth Companies).